Stock Ratings / Health Care / STIM / options

PDEX (58) KTWO (59) UTMD (62) PROF (36) ⌘ Pro Terminal →

Neuronetics Inc. (STIM) Options Positioning, Max Pain & Unusual Sweeps

Q: Where is STIM trading relative to its 50-day, 200-day, and 52-week technical levels?

STIM last traded at $2.25 (-5.46% on volume of 1,089,358 shares), positioning the stock -10.36% below its 50-day simple moving average ($2.51) and +19.68% above its 200-day simple moving average ($1.88). Across its 52-week range of $0.80 to $3.44, STIM sits at the 54.9% percentile with a 14-day RSI of 55.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($1.97 to $2.53).

Q: What is STIM's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for STIM.

$2.25 -5.46% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.22

Neuronetics Inc. (STIM) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $181.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on STIM Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is STIM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Neuronetics Inc. (NASDAQ: STIM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $2.25 (-5.46% 1D, market cap $181.3M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, STIM ranks #850 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does STIM compare to PDEX and KTWO in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), STIM carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 48.5%, and ROIC of -35.0%. By comparison, PDEX (Pro-Dex Inc.) holds a D+ grade (58/100 RQD, P/E 22.2x, ROIC 23.2%, cap $199.2M) and KTWO (K2 Capital Acquisition Corporation Class A Ordinary Share) posts a C- grade (59/100 RQD, P/E N/A, ROIC —, cap $202.8M). Among the 5-stock peer group, PDEX leads on earnings multiple (22.2x) while UTMD leads on capital efficiency (26.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for STIM?

▼

Per STIM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001227636), Neuronetics Inc. generated $149.2M in revenue (+99.2% YoY), -$39.0M in net income, and -$20.4M in free cash flow against $141.6M in total assets and $65.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.22 (-1.17%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-12.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for STIM)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (30/100 Composite)

🔍 WHY STIM SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (37% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+6/20 pts (20% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$2.13-10.3% Next Q

Q2 (-2Q)

Grade E$1.91+17.3% Next Q

Q3 (-1Q)

Grade E$2.24+0.4% Next Q

Current

Grade E$2.25-9.6% Hist 90D α

Trajectory: E (22) → E (30)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a STIM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While STIM currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.51) and Max Pain ($2.36) forces dealer call-delta covering toward $3.61.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $STIM• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “STIM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 30%NO 70%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (STIM)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for STIM.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring STIM)

✓Walkthrough of STIM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

STIM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +11.39%▲ ASCENDING CHANNEL

2026-11-02O $2.26H $2.38L $2.25C $2.25VOL 832.3K

RES: $3.98SUP: $1.94SMA50: $2.51SMA200: $1.88

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

STIM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 STIM Butterfly Map → + Track STIM →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +99.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on STIM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for STIM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for STIM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (STIM)

Health Care Rank #850 of 1016 ⚔️ PDEX vs STIM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (STIM vs. PDEX, KTWO, UTMD, PROF)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Neuronetics Inc. (STIM) ranks #850 by composite RQD confidence (30/100, grade E) and #588 by equity capitalization ($181.3M). Within this direct 5-issuer industry benchmark cohort, PDEX leads on earnings valuation at 22.2x trailing P/E, while UTMD leads on capital efficiency and profitability with 26.9% ROIC and 57.1% gross margin. UTMD currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with STIM at 30/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
STIM ACTIVE Neuronetics Inc.	E	30/100	—	48.5%	-35.0%	-5.46%	$181.3M	Benchmark Subject
PDEX Pro-Dex Inc.	D+	58/100	22.2x	29.3%	23.2%	-5.58%	$199.2M	/pdex-vs-stim →
KTWO K2 Capital Acquisition Corporation Class A Ordinary Share	C-	59/100	—	—	—	-0.30%	$202.8M	/ktwo-vs-stim →
UTMD Utah Medical Products Inc.	C	62/100	—	57.1%	26.9%	+1.91%	$212.7M	/utmd-vs-stim →
PROF Profound Medical Corp.	D-	36/100	—	70.8%	-35.0%	+12.12%	$214.1M	/prof-vs-stim →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001227636

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Neuronetics Inc. (STIM) reported GAAP revenue of $149.2M (+99.2% vs. FY2024 revenue of $74.9M , and +109.1% cumulative change since FY2023) , GAAP net income of -$39.0M, operating cash flow of -$20.4M, and free cash flow of -$20.4M (+34.2% YoY). On the balance sheet, STIM closed FY2025 with $141.6M in total assets against $65.8M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$149.2M	-$39.0M	-$20.4M	-$20.4M	$141.6M	$65.8M
FY2024 (FY)	2024-12-31	$74.9M	-$43.7M	-$31.0M	-$31.0M	$140.9M	$55.2M
FY2023 (FY)	2023-12-31	$71.3M	-$30.2M	-$32.0M	-$32.0M	—	—

3. STIM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is STIM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does STIM compare to PDEX and KTWO in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for STIM?

Where is STIM trading relative to its 50-day, 200-day, and 52-week technical levels?

STIM last traded at $2.25 (-5.46% on volume of 1,089,358 shares), positioning the stock -10.36% below its 50-day simple moving average ($2.51) and +19.68% above its 200-day simple moving average ($1.88). Across its 52-week range of $0.80 to $3.44, STIM sits at the 54.9% percentile with a 14-day RSI of 55.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($1.97 to $2.53).

STIM Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is STIM's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for STIM.

Direct Sub-Reports: STIM RQD Cockpit STIM 12M Forecast STIM Earnings & Move STIM Dividends & DRIP STIM Insiders & 13F STIM Whale Options STIM Profit Sankey STIM News & Why

ROARABLE RATING BRIEF • RQD 30/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

STIM — Neuronetics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:41:48Z

Roarable Rating Brief: What This Means to a Prospective Investor

The per the Roarable RQD rating, STIM scores 30 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

Fundamental Cash Engine: 5 / 20 — ROIC of -35% and FCF yield of -11.25%. The cash-generation pillar is the weakest contributor to the score, indicating the business is consuming rather than producing cash on this measure.
Whale 13F Flow: 11 / 20 — Reflects institutional accumulation and options positioning. This is the strongest pillar, though still below half of its maximum.
Insider Conviction: 3 / 20 — Reflects SEC Form 4 and Congressional PTR cluster flow. This is among the lowest pillar scores and signals limited insider-side confidence per the rating's inputs.
Macro Regime Fit: 5 / 20 — Beta of 1.0 and sector sensitivity. The score suggests the stock's macro positioning offers little favorable regime alignment.
Forensic Balance Sheet: 6 / 20 — Altman Z of 0.2, Piotroski F of 5/9, and Debt/Equity of 2.94. Per the SEC financials and rating inputs, these readings point to elevated balance-sheet and solvency risk.

For a prospective investor evaluating the stock today, the rating's composition matters: the weakest pillars (cash engine, insider conviction, balance sheet, macro fit) all point in the same direction, while the institutional-flow pillar is the only one with meaningful support. Upside drivers would need to come from a reversal in cash generation or balance-sheet repair, neither of which is evidenced in the source data. The stock's 52-week range of $0.8 - $3.44 against a current price of 2.38 shows substantial price volatility, which the rating treats as a risk characteristic rather than a signal of value.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$149.2M	$-31.4M	$-39.0M	N/A	$-20.4M	$28.1M	$65.8M
FY 2024	$74.9M	$-34.6M	$-43.7M	N/A	$-31.0M	$18.5M	$55.2M
FY 2023	$71.3M	$-30.6M	$-30.2M	N/A	$-32.0M	N/A	N/A

Per the market data section, gross margin is 48.5%, operating margin is -21.1%, and net margin is -26.1%, with ROIC of -35%. Per the RQD rating, the Altman Z-Score is 0.2 and the Piotroski F-Score is 5/9. The balance sheet shows a Debt/Equity ratio of 2.94 per the rating inputs. Reported operating and net losses persist across all three periods shown.

Open Questions

What are the specific drivers behind the negative FCF and ROIC, and is there a path to positive cash generation?
What is the composition and maturity schedule of the $65.8M debt, and how does it relate to the 2.94 Debt/Equity reading?
What were the contents and outcome of the scheduled November 4 results referenced in the news wire?
What are the company's core products, customer concentration, and revenue mix?
Why are EPS, P/E, and EV/EBITDA unavailable, and what would they show on a normalized basis?

STIM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Neuronetics Inc. (STIM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to STIM Debate Forum (3) ↓

🟡 MARKET WIRE StockInvest.us • 2h ago

Neuronetics Stock Price Forecast. Should You Buy STIM?

StockInvest.us report covering Neuronetics Inc. (STIM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 5h ago

Neuronetics, Inc. (STIM) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Neuronetics Inc. (STIM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 8h ago

Neuronetics: Transforming From Device Manufacturer To Psychedelic Infrastructure (STIM)

Seeking Alpha report covering Neuronetics Inc. (STIM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 11h ago

Starling Oncology (STLN) Stock Gets Fair Value Boost On Capitated Revenue And Nexus Views

Yahoo Finance report covering Neuronetics Inc. (STIM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 14h ago

Neuronetics schedules November 4 results for Neuronetics stock

ad-hoc-news.de report covering Neuronetics Inc. (STIM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 20h ago

Beta Bionics, Inc. (BBNX) Reports Q3 Loss, Beats Revenue Estimates

Yahoo Finance report covering Neuronetics Inc. (STIM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 12d ago

Neuronetics to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call

MALVERN, Pa., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook netwo

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 12d ago

Integra LifeSciences (IART) Surpasses Q3 Earnings Estimates

Integra (IART) delivered earnings and revenue surprises of +5.36% and -0.81%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

STIM Bull vs. Bear Conversation Board — What's Your Call at $2.25?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON STIM 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $2.09 (-12.2%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is STIM (E • RQD 30/100) a Buy at $2.38?

Welcome to the STIM (Neuronetics Inc.) Roar Pit. Current RQD Composite is 30/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.98 (-16.8%)

Spot @ $2.38

Pump the brakes on STIM — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on STIM, but look at what you are paying: current EV/EBITDA multiples with 48.5% gross margins. Unless Neuronetics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $2.98 (+25.2%)

Spot @ $2.38

STIM cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on STIM, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $2.38 (52-wk range $0.80 - $3.44), any beat on forward guidance forces shorts and underweight funds to chase.